The only color the company provided with regard to
Post# of 72440
Since that will be a trial with a pill and likely a phase 2a or small phase 2, it probably won't cost too much money. Probably in the range of $5-15 million.
Given those parameters, the upfront B-UP payment was likely $5-15M or less. If it was considerably more I would have expected verbage confirming that the B-UC trial would be completely covered along with some Kevetrin development expenses.
Just one man's opinion.